Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 17/20 | 0.62 |
| ▸ | PKD1 | P98161 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16532476 | 0.89 | MAP3K14 (0.79) | MAP3K14 | |
| SCHEMBL18888186 | 0.82 | MAP3K14 (0.68) | MAP3K14MEN1KMT2A | |
| SCHEMBL16532435 | 0.78 | MAP3K14 (0.63) | MAP3K14 | |
| SCHEMBL16532313 | 0.78 | PDE4A (0.48) | MAP3K14PKD1KCNH2CYP1A2CYP3A4 | |
| SCHEMBL16532559 | 0.77 | MAP3K14 (0.62) | MAP3K14 | |
| SCHEMBL16532298 | 0.77 | MAP3K14 (1.00) | MAP3K14PKD1 | |
| SCHEMBL16532512 | 0.76 | MAP3K14 (0.81) | MAP3K14 | |
| SCHEMBL16516753 | 0.76 | MAP3K14 (1.00) | MAP3K14PKD1 | |
| SCHEMBL20916168 | 0.74 | MAP3K14 (0.83) | MAP3K14PKD1 | |
| SCHEMBL16532517 | 0.73 | MAP3K14 (0.81) | MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | MAP3K14 514/4885PKD1 2902/4885MEN1 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.